IMMUNE-RELATED ADVERSE EVENT
Clinical trials for IMMUNE-RELATED ADVERSE EVENT explained in plain language.
Never miss a new study
Get alerted when new IMMUNE-RELATED ADVERSE EVENT trials appear
Sign up with your email to follow new studies for IMMUNE-RELATED ADVERSE EVENT, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo aims to boost immunotherapy in elderly melanoma patients
Disease control Recruiting nowThis Phase 2 trial tests whether adding thymosin alpha 1 to the immunotherapy drug toripalimab can help elderly patients (60+) with advanced melanoma. The study will enroll 55 participants and measure how many patients' tumors shrink or disappear. Researchers also want to see if …
Matched conditions: IMMUNE-RELATED ADVERSE EVENT
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Could a simple asthma drug prevent a dangerous immunotherapy side effect?
Disease control Recruiting nowThis study tests whether using inhaled budesonide (a steroid commonly used for asthma) for one year can stop lung inflammation from coming back in cancer patients who had a serious immune reaction to immunotherapy. About 94 adults with solid tumors who recently had lung inflammat…
Matched conditions: IMMUNE-RELATED ADVERSE EVENT
Phase: PHASE2 • Sponsor: AHS Cancer Control Alberta • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New hope for cancer patients: drug may cut steroid need for immunotherapy side effect
Symptom relief Recruiting nowThis study tests whether the drug adalimumab can help people with arthritis caused by cancer immunotherapy use less steroids. About 30 adults will be randomly assigned to receive either adalimumab or standard steroid treatment. The goal is to see if adalimumab can control arthrit…
Matched conditions: IMMUNE-RELATED ADVERSE EVENT
Phase: PHASE2 • Sponsor: Tom Appleton • Aim: Symptom relief
Last updated Jun 27, 2026 09:09 UTC